ZDHHC4

Across TCGA pan-cancer cohorts, ZDHHC4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZDHHC4 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZDHHC4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ZDHHC4 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where ZDHHC4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.299	0.670	.001	17	view →
LUAD	DFS	Quartile	All	0.264	0.881	.001	8	view →
LSCC	DFS	Quartile	All	0.852	0.562	.015	4	view →
HNSC	DFS	Tertile	III,IV	0.822	0.522	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZDHHC4–PDAC (OS)

Open the PDAC breakdown →